# Recommendation: NO-GO for clinical use

**2026-10-15 — Do not enable real HH pathology intake on the reviewed configuration.** Installation planning and isolated synthetic commissioning can proceed, with the existing pathology review process retained. Source review of phases 0–10 is complete; unavailable appliance/site acceptance checks remain open. No project source was changed and no HH system was contacted.

The three reviewed commits are unchanged from review 1. The [36 consolidated findings](findings.md) comprise **5 CRITICAL, 22 HIGH, 6 MEDIUM and 3 LOW**. The [prior register](prior-findings-status.md) rechecks **294 source items: 83 fixed, 211 open, no verified regressions**; this includes overlapping findings and suggestions, not 294 distinct defects.

The five critical blockers are:

- **R2-18:** image-only and zero-byte PDFs can produce empty analysis input without a mandatory readability/review gate. Synthetic production-code probes reproduced empty extraction.
- **R2-19:** incomplete JSON objects, including `{}` with MAX_TOKENS, are accepted as successful analysis. Production response-handler probes reproduced this.
- **R2-20:** a low-confidence or context-deficient negative has no explicit human-review branch in the available graph.
- **R2-11:** SMTP failure prevents MFA login and can roll back its own failure alert. Host recovery exists, but must be rehearsed and independently monitored.
- **R2-06:** failed restore can destroy the displaced database without a database snapshot to return to.

Release readiness also fails independently: **the schema-freeze guard rejects this baseline and strict dependency verification fails** (R2-35/R2-01). The production HH provisioning bundle and immutable model/prompt manifest were not supplied (R2-17/R2-31). No held-out clinical sensitivity or calibration evidence establishes safety-net performance (R2-30). Mail delivery/retry/alert gaps, required graph outcomes, mount detection, backup protection and harness acceptance contradictions need closure and demonstrated operating procedures.

Local evidence is substantial but narrower than deployment acceptance: the initial 2,806-case backend run had two root-permission failures and seven skips; the focused 40-case rerun passed with filesystem bypass removed. Frontend 661 tests, 37 mockup checks and fresh build/type-check passed. Harness ran 579 bats cases plus 150 Python tests; targeted reruns resolved permission/layout skips, and seven nginx container checks passed. **Fourteen NER integration cases, five disabled gateway demos, five minisign cases and one native nginx syntax case remain skipped.** The aggregate build is recorded as failed with resolved test causes, not relabelled green. Full results are in [00-baseline.md](00-baseline.md).

Before approval, complete the [owner checklist](go-live-checklist.md) for an immutable release: correct the clinical input/output/uncertainty paths, prove all required outcomes, freeze/test migrations and safe recovery, supply signed artifacts/site definitions, and obtain HH clinical/security acceptance of measured results. The [install kit](install-kit.md) provides the worksheet, synthetic matrix and rollback plan; [open questions](open-questions.md) lists missing facts.

GPU/ARM64 fit, real NER/OCR inference, TPM/LUKS, relay/mailbox, SMB/NFS, boot/outage recovery, replacement restore, authenticated accessibility and full clinical evaluation were unavailable here. They require recorded appliance/site verification. Residual LOW issues may be accepted explicitly with owners/deadlines; package advisories without established pilot reachability are not claimed as confirmed exploits. No false-negative rate, successful disaster recovery or compliance certification is inferred from this review.
